Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Genprex ( (GNPX) ) has issued an announcement.
On October 28, 2025, Genprex, Inc. announced a securities purchase agreement for a registered direct offering of 377,780 shares of common stock at $9.00 per share, expected to close on October 29, 2025. The offering includes a concurrent private placement of warrants for up to 755,560 shares, with potential gross proceeds of $6.6 million if fully exercised. The company plans to use the net proceeds, estimated at $3.0 million, for working capital and general corporate purposes. This move is part of Genprex’s strategy to strengthen its financial position and support its ongoing clinical programs.
More about Genprex
Genprex, Inc. is a clinical-stage gene therapy company focused on developing therapies for cancer and diabetes. The company utilizes its Oncoprex Delivery System for oncology treatments and has a diabetes gene therapy approach using an AAV vector. Genprex collaborates with institutions to develop drug candidates for large patient populations with limited treatment options.
Average Trading Volume: 701,730
Technical Sentiment Signal: Sell
Current Market Cap: $8.72M
For an in-depth examination of GNPX stock, go to TipRanks’ Overview page.